You are here: Industry Insights > Venclexta

News List

FDA Approves Roche’s Venclexta for CLL contractpharma
June 12, 2019
Venclexta combined with Gazyva is an approved chemotherapy-free option for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).
AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients drugs
May 22, 2019
AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients.
Venclexta safety warnings in multiple myeloma patients pharmatimes
March 27, 2019
The US Food and Drug Administration (FDA) has posted a safety statement to alert healthcare professionals and patients about the suspension of a clinical trial of bortezomib and low-dose dexamethasone with or without Venclexta (venetoclax).
Venclexta trial deaths force AbbVie, Roche to stop recruiting myeloma patients fiercepharma
March 20, 2019
AbbVie and Roche are looking to move key oncology drug Venclexta deeper into the blood cancer arena, but their ambitions in multiple myeloma just took a hit.
AbbVie, Roche eye first-line use of Venclexta in leukaemia pharmaphorum
December 17, 2018
AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena......
Roche’s Venclexta filed in the US for acute myeloid leukemia pharmatimes
July 16, 2018
The submission is seeking approval for use of the drug, in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously untreated AML who are ineligible for intensive chemotherapy.
Roche’s Venclexta filed in the US for acute myeloid leukemia pharmatimes
July 13, 2018
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).
US nod for Venclexta/Rituxan combo pharmatimes
July 10, 2018
US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen's Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

Previous page 1 2 Next page